GSK - Conference and earnings call announcements

Strategic collaboration with GSK expanded to accelerate clinical development of alpibectir for the treatment of tuberculosisGSK to participate in Series C Extension with equity investmentSeries C financing round extended overall by CHF 12.3 million to CHF 44.9 million BASEL, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant ("MDR") bacteria, announced today the expansion of its strategic collaboration with the global biopharma company GSK plc (NYSE:GSK) to accelerate the clinical develo

Special Meeting to be held on June 16, 2023 BELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS" or the "Company") today announced that the Superior Court of Québec has issued an interim order authorizing, among other things, the holding of a special meeting (the "Special Meeting") of shareholders of BELLUS ("Shareholders") on June 16, 2023. At the Special Meeting, Shareholders will be asked to consider and, if deemed advisable, to adopt a special resolution (the "Arrangement Resolution") approving the previously-announced statutory plan of arrangement under section 192 of the Canada Business Corporations Act (the "Arrangement") pursuant to which 14934792 Canada Inc. (the "Purchaser"), a co

ORLANDO, FL / ACCESSWIRE / January 24, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a pioneer in the science of using novel transdermal solutions and other innovative technologies, today announced details of the Company's participation at the 2023 Transdermal and Microneedle Conference taking place January 23-24, 2023, at the Copthorne Tara Hotel, London, United Kingdom.Gareth Sheridan, Nutriband's CEO, will give a presentation at 11:00 a.m. GMT on January 24th entitled ‘Improving existing transdermal technologies to reduce the liability profile of abusable medications' which will provide an overview of the development of transdermal drug delivery systems using Nutriband's AVERSA techn

ORLANDO, FL / ACCESSWIRE / October 17, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) ("Nutriband" or the "Company") today announced that it has accepted an invitation as a guest speaker for the 2023 Transdermal and Microneedle Conference to be held in London on January 23 and 24. The Company's presentation will be on ‘Improving existing transdermal technologies to reduce the liability profile of abusable medications' which will discuss our AVERSA technology as a reference point. Nutriband CEO, Gareth Sheridan, will be speaking on behalf of the Company.The Company was also invited to participate as a panelist for a discussion to take place on the topic of microneedles as a therapeutic too

JERUSALEM, Israel, Nov. 24, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), which focuses on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, reports that the Annual General Meeting (AGM) of Shareholders of the Company will be held on December 27, 2021 in Tel Aviv, Israel. Resolutions to be voted upon at the AGM include the election of Mr. Jay Green to the Company's Board of Directors. Mr. Green recently completed a six-year term as Senior Vice President Finance and

Alector and GSK to co-develop progranulin-elevating monoclonal antibodies, AL001 and AL101, for a range of neurodegenerative diseases, including frontotemporal dementia, amyotrophic lateral sclerosis, Parkinson's disease and Alzheimer's diseaseCompanies will co-commercialize and share profits in the US; GSK will retain exclusive commercialization rights outside the USAlector will receive $700 million in upfront payments, up to $1.5 billion in potential milestone payments, profit sharing and royaltiesAlector management to host conference call today at 8:30 a.m. ET SOUTH SAN FRANCISCO, Calif. and LONDON, July 02, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC) and GlaxoSmithKline plc

WARREN, N.J., Feb. 1, 2021 /PRNewswire/ -- GlaxoSmithKline (LSE: GSK) (NYSE: GSK) – This year, the #TUMSBingoSweepstakes is the BIG GAME within the BIG GAME and takes place on a day known for indulging in heartburn-inducing food and fans experiencing TUMSworthy moments. TUMS®, America's #1 heartburn medicine that provides fast-acting relief from the pain of heartburn, today is launching the first-ever #TUMSBingoSweepstakes - an interactive digital game of bingo featuring dozens of heartburn-inducing moments that could happen on or off the field. The #TUMSBingoSweepstakes gives both hardcore and casual fans an opportunity to participate in all of the action and earn a chance to win a piece

INDIANAPOLIS and SAN FRANCISCO and LONDON, Jan. 27, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced a collaboration to evaluate a combination of two COVID-19 therapies in low-risk patients with mild to moderate COVID-19. Lilly has expanded its ongoing BLAZE-4 trial to evaluate the administration of bamlanivimab (LY-CoV555) 700mg with VIR-7831 (also known as GSK4182136) 500mg, two neutralizing antibodies that bind to different epitopes of the SARS-CoV-2 spike protein. This unique collaboration marks the first time that monoclonal antibodies from separate companies will be brought together

INDIANAPOLIS, SAN FRANCISCO and LONDON, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced a collaboration to evaluate a combination of two COVID-19 therapies in low-risk patients with mild to moderate COVID-19. Lilly has expanded its ongoing BLAZE-4 trial to evaluate the administration of bamlanivimab (LY-CoV555) 700mg with VIR-7831 (also known as GSK4182136) 500mg, two neutralizing antibodies that bind to different epitopes of the SARS-CoV-2 spike protein. This unique collaboration marks the first time that monoclonal antibodies from separate companies will be brought together